Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats

Yaman, Hüseyin; kahraman, cemil

doi:10.3906/sag-2011-76

Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats

Cemil KAHRAMAN, (Düzce Üniversitesi, Sağlık Bilimleri Fakültesi, Biyokimya Bölümü, Düzce, Türkiye)

Hüseyin YAMAN (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Trabzon, Türkiye)

Turkish Journal of Medical Sciences

5 0

Yıl: 2021 Cilt: 51 Sayı: 3 Sayfa Aralığı: 1571 - 1577 Metin Dili: İngilizce DOI: 10.3906/sag-2011-76 İndeks Tarihi: 20-01-2022

Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats

Öz:

Background/aim: Hyperbaric oxygen therapy (HBOT) causes insulin sensitivity, but the reason for this is not known yet. The aim of the present study was to investigate the effect of HBOT on insulin sensitivity via resistin, plasminogen activator inhibitor-I (PAI-I), and adiponectin. Materials and methods: The study was designed using HBOT and control groups, with eight rats in each group. After 20 days of HBOT under 2.5 atmospheres for 90 min, the fasting insulin (FI), resistin, PAI-I, homeostatic model assessment of insulin resistance scores (HOMA–IR), quantitative insulin sensitivity check index (QUICKI), fasting plasma glucose (FPG), triglyceride, and high-density lipoprotein cholesterol (HDL-C) in the plasma were measured. The resistin, PAI-I, and adiponectin mRNA expression levels were also measured in the adipose tissue. Results: Compared to the control group, the FI, FPG, and HOMA-IR scores were significantly lower in the HBOT group, whereas the HDL-C and QUICKI scores were found to be higher. In addition, the resistin, adiponectin, and PAI-I mRNA expression levels were also higher in the HBOT group. Conclusion: The present study demonstrated that the HBOT had regulated the FI, FPG, and HDL-C associated with metabolic syndrome and diabetes mellitus. Moreover, the study showed that HBOT causes insulin sensitivity by raising adiponectin.Key words: Adiponectin, insulin, insulin sensitivity, resistin, plasminogen activator inhibitor-I

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Weaver LK. Hyperbaric oxygen therapy indications. 13th ed. North Palm Beach, FL, USA: Best Publishing Company; 2014.
2. Jain KK. Physical, physiological, and biochemical aspects of hyperbaric oxygenation. In: Jain KK (editor). Textbook of Hyperbaric Medicine. 6th ed. Cham, Switzerland: Springer; 2017. pp. 11-21.
3. Kumar MA, Radhika B, Gollamudi N. Hyperbaric oxygen therapy- a novel treatment modality in oral submucous fibrosis: a review. Journal of Clinical and Diagnostic Research 2015; 9 (5): 1-4. doi: 10.7860/JCDR/2015/11500.5905
4. McMonnies CW. Hyperbaric oxygen therapy and the possibility of ocular complications or contradictions. Clinical and Experimental Optometry 2015; 98 (2): 122-125. doi: 10.1111/cxo.12203
5. Simsek K, Sadir S, Oter S. The relation of hyperbaric oxygen with oxidative stress- reactivemolecules in action. Oxidants Antioxidants in Medical Sciences 2015; 4 (1): 17-22. doi: 10.5455/oams.010415.rv.016
6. Berner JE, Vidal P, Will P, Castillo P. Use of hyperbaric oxygenation for wound management. Revista Medica de Chile 2014; 142 (12): 1575-1583. doi: 10.4067/S0034- 98872014001200011
7. Bhutani S, Vishwanath G. Hyperbaric oxygen and wound healing. Indian Journal of Plastic Surgery 2012; 45 (2): 316- 324. doi: 10.4103/0970-0358.101309
8. Vorn R, Yoo HY. Effects of high glucose with or without other metabolic substrates on alpha-adrenergic contractions in rat mesenteric and femoral arteries. Korean Journal of Physiology Pharmacology 2017; 21 (1): 91-97. doi: 10.4196/ kjpp.2017.21.1.91
9. Iso H, Naito Y, Sato S, Kitamura A, Okamura T et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. American Journal of Epidemiology 2001; 153 (5): 490-499. doi: 10.1093/aje/153.5.490
10. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. American Journal of Medicine 1997; 62 (5): 707-714. doi: 10.1016/0002- 9343(77)90874-9
11. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine 2007; 357 (13): 1301-1310. doi: 10.1056/NEJMoa064278
12. Freeman AM, Pennings N. Insulin Resistance. Florida, USA: StatPearls Publishing; 2019.
13. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 2005; 6 (1): 13-21. doi: 10.1111/j.1467-789X.2005.00159.x
14. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, JuhanVague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46 (5): 860- 867. doi: 10.2337/diab.46.5.860
15. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Current Opinion in Lipidology 2007; 18 (3): 240-245. doi: 10.1097/ MOL.0b013e32814e6d29
16. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. British Journal of Pharmacology 2012; 165 (3): 622-632. doi: 10.1111/j.1476-5381.2011.01369.x
17. Wilkinson D, Chapman IM, Heilbronn LK. Hyperbaric oxygen therapy improves peripheral insulin sensitivity in humans. Diabetic Medicine 2012; 29 (8): 986-989. doi: 10.1111/j.1464- 5491.2012.03587.x
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25 (4): 402-408. doi: 10.1006/ meth.2001.1262
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 2004; 27 (6): 1487-1495. doi: 10.2337/ diacare.27.6.1487
20. McMillin JM. Blood glucose. In: Walker HK, Hall WD, Hurst JW (editors). Clinical Methods. 3rd ed. Boston, MA, USA: Butterworths; 1990. pp. 662-665.
21. Yasuda K, Adachi T, Gu N, Matsumoto A, Matsunaga T et al. Effects of hyperbaric exposure with high oxygen concentration on glucose and insulin levels and skeletal muscle-fiber properties in diabetic rats. Muscle Nerve 2007; 35 (3): 337-343. doi: 10.1002/mus.20692
22. Whitworth JA, Williamson PM, Brown MA, Colman P. Hyperinsulinemia is not a cause of cortisol-induced hypertension. American Journal of Hypertension 1994; 7 (6): 562-565. doi: 10.1093/ajh/7.6.562
23. Lund V, Kentala E, Scheinin H, Klossner J, Koskinen P, Jalonen J. Effect of hyperbaric conditions on plasma stress hormone levels and endothelin-1. Undersea and Hyperbaric Medicine 1999; 26 (2): 87-92.
24. Bermudez V, Salazar J, Martínez MS, Chávez-Castillo M, Olivar LC et al. Prevalence and associated factors of insulin resistance in adults from Maracaibo City, Venezuela. Advances in Preventive Medicine 2016; 2016: 1-13. doi: 10.1155/2016/9405105
25. Gutch M, Kumar S, Razi S, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian Journal of Endocrinology and Metabolism 2015; 19 (1): 160-164. doi: 10.4103/2230- 8210.146874
26. Semadi IN, Irawan H. Blood glucose and lipid profile in patients with diabetic foot ulcer that underwent hyperbaric oxygen therapy. Bali Medical Journal 2017; 6 (2): 405-408. doi: 10.15562/bmj.v6i2.606
27. März W, Kleber ME, Scharnag H, Speer T, Zewinger S et al. HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology 2017; 106 (9): 663-675. doi: 10.1007/ s00392-017-1106-1
28. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. Journal of Clinical Investigation 1990; 85 (4): 1234-1243. doi: 10.1172/JCI114558
29. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK et al. Major lipids, apolipoproteins, and risk of vascular disease. Journal of American Medical Association 1993; 302 (18): 1993- 2000. doi: 10.1001/jama.2009.1619
30. Limin S, Junhua Y, Yuan L, Di Z, Caishun Z, Qian L et al. Ghrelin system is involved in improvements in glucose metabolism mediated by hyperbaric oxygen treatment in a streptozotocininduced type 1 diabetes mouse model. Molecular Medicine Reports 2020; 22 (5): 3767-3776. doi: 10.3892/mmr.2020.11481
31. Liu Y, Zhang D, Yuan J, Song L, Zhang C et al. Hyperbaric oxygen ameliorates insulin sensitivity by increasing GLUT4 expression in skeletal muscle and stimulating UCP1 in brown adipose tissue in T2DM mice. Frontiers in Endocrinology (Lausanne) 2020; 11 (32): 1-11. doi: 10.3389/fendo.2020.00032
32. Wilkinson D, Nolting M, Mahadi MK, Chapman I, Heilbronn L. Hyperbaric oxygen therapy increases insulin sensitivity in overweight men with and without type 2 diabetes. Diving and Hyperbaric Medicine 2015; 45 (1): 30-36.
33. Xu Q, Wei Y, Fan S, Wang L, Zhou X. Repetitive hyperbaric oxygen treatment increases insulin sensitivity in diabetes patients with acute intracerebral hemorrhage. Neuropsychiatric Disease and Treatment 2017; 10 (13): 421-426. doi: 10.2147/ NDT.S126288
34. Vera-Cruz P, Guerreiro F, Ribeiro MJ, Guarino MP, Conde SV. Hyperbaric oxygen therapy improves glucose homeostasis in type 2 diabetes patients: A likely involvement of the garotid bodies. Advances in Experimental Medicine and Biology 2015; 860: 221-225. doi: 10.1007/978-3-319-18440-1_24
35. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR et al. The hormone resistin links obesity to diabetes. Nature 2001; 409 (6818): 307-312. https://doi.org/10.1038/35053000
36. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor. Diabetes 2004; 53 (2): 336- 346. doi: 10.2337/diabetes.53.2.336
37. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annual Review of Biochemistry 2010; 79 (1): 351-379. doi: 10.1146/annurevbiochem-060308-103103

APA	kahraman c, Yaman H (2021). Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. , 1571 - 1577. 10.3906/sag-2011-76
Chicago	kahraman cemil,Yaman Hüseyin Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. (2021): 1571 - 1577. 10.3906/sag-2011-76
MLA	kahraman cemil,Yaman Hüseyin Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. , 2021, ss.1571 - 1577. 10.3906/sag-2011-76
AMA	kahraman c,Yaman H Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. . 2021; 1571 - 1577. 10.3906/sag-2011-76
Vancouver	kahraman c,Yaman H Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. . 2021; 1571 - 1577. 10.3906/sag-2011-76
IEEE	kahraman c,Yaman H "Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats." , ss.1571 - 1577, 2021. 10.3906/sag-2011-76
ISNAD	kahraman, cemil - Yaman, Hüseyin. "Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats". (2021), 1571-1577. https://doi.org/10.3906/sag-2011-76

APA	kahraman c, Yaman H (2021). Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences, 51(3), 1571 - 1577. 10.3906/sag-2011-76
Chicago	kahraman cemil,Yaman Hüseyin Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences 51, no.3 (2021): 1571 - 1577. 10.3906/sag-2011-76
MLA	kahraman cemil,Yaman Hüseyin Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences, vol.51, no.3, 2021, ss.1571 - 1577. 10.3906/sag-2011-76
AMA	kahraman c,Yaman H Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences. 2021; 51(3): 1571 - 1577. 10.3906/sag-2011-76
Vancouver	kahraman c,Yaman H Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences. 2021; 51(3): 1571 - 1577. 10.3906/sag-2011-76
IEEE	kahraman c,Yaman H "Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats." Turkish Journal of Medical Sciences, 51, ss.1571 - 1577, 2021. 10.3906/sag-2011-76
ISNAD	kahraman, cemil - Yaman, Hüseyin. "Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats". Turkish Journal of Medical Sciences 51/3 (2021), 1571-1577. https://doi.org/10.3906/sag-2011-76